Algert Global LLC Savara Inc Transaction History
Algert Global LLC
- $4.04 Billion
- Q1 2025
A detailed history of Algert Global LLC transactions in Savara Inc stock. As of the latest transaction made, Algert Global LLC holds 132,968 shares of SVRA stock, worth $269,925. This represents 0.01% of its overall portfolio holdings.
Number of Shares
132,968
Previous 132,968
-0.0%
Holding current value
$269,925
Previous $408,000
9.8%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding SVRA
# of Institutions
142Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$49.7 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$35.7 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$25.1 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$23.3 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$22.3 Million2.18% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $232M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.